Promising Treg Drug for Eczema Shows Asthma Benefits in Phase IIb
A groundbreaking interleukin (IL)-2 receptor agonist and regulatory T-cell (Treg) proliferator, known as rezpegaldesleukin, has demonstrated substantial improvements in managing atopic dermatitis, along with encouraging secondary effects for patients dealing with coexisting asthma, according to findings from the phase IIb…